
NYSTATIN- nystatin cream NuCare Pharmaceuticals,Inc.

Nystatin Cream USP, 100,000 units per gram

FOR TOPICAL USE ONLY. NOT FOR OPHTHALMIC USE

DESCRIPTION

Nystatin is a polyene antifungal antibiotic obtained from *Streptomyces nursei*. Structural formula:



Molecular formula	: C ₄₇ H ₇₅ NO ₁₇
Molecular weight	: 926.09 g/mol

Nystatin cream is for dermatologic use.

Nystatin cream, USP for topical use, contains 100,000 USP nystatin units per gram. Inactive ingredients: aluminium hydroxide gel, ceteareth-15, mono- and di- glyceride, polyoxyl 8 stearate, propylene glycol, simethicone emulsion, sorbitol solution, titanium dioxide, white petrolatum, methylparaben and propylparaben.

CLINICAL PHARMACOLOGY

Pharmacokinetics

Nystatin is not absorbed from intact skin or mucous membrane.

Microbiology

Nystatin is an antibiotic which is both fungistatic and fungicidal *in vitro* against a wide variety of yeasts and yeast-like fungi, including *Candida albicans, C. parapsilosis, C. tropicalis, C. guilliermondi, C. pseudotropicalis, C. krusei, Torulopsis glabrata, Tricophyton rubrum, T. mentagrophytes.* Nystatin acts by binding to sterols in the cell membrane of susceptible species resulting in a change in membrane permeability and the subsequent leakage of intracellular components. On repeated subculturing with increasing levels of nystatin does not develop during therapy. However, other species of *Candida* (*C. tropicalis, C. guilliermondi, C. krusei, and C. stellatoides*) become quite resistant on treatment with nystatin and simultaneously become cross resistant to amphotericin as well. This resistance is lost when the antibiotic is removed. Nystatin exhibits no appreciable activity against bacteria, protozoa, or viruses.

INDICATIONS AND USAGE

Nystatin cream is indicated in the treatment of cutaneous or mucocutaneous mycotic infections caused by *Candida albicans* and other susceptible *Candida* species.

This cream is not indicated for systemic, oral, intravaginal or ophthalmic use.

CONTRAINDICATIONS

Nystatin cream is contraindicated in patients with a history of hypersensitivity to any of their components.

PRECAUTIONS

General

Nystatin cream should not be used for the treatment of systemic, oral, intravaginal or ophthalmic infections.

If irritation or sensitization develops, treatment should be discontinued and appropriate measures taken as indicated. It is recommended that KOH smears, cultures, or other diagnostic methods be used to confirm the diagnosis of cutaneous or mucocutaneous candidiasis and to rule out infection caused by other pathogens.

INFORMATION FOR PATIENTS

Patients using these medications should receive the following information and

instructions:

1. The patient should be instructed to use these medications as directed (including the replacement of missed doses). This medication is not for any disorder other than that for which it is prescribed.

2. Even if symptomatic relief occurs within the first few days of treatment, the patient should be advised not to interrupt or discontinue therapy until the prescribed course of treatment is completed.

3. If symptoms of irritation develop, the patient should be advised to notify the physician promptly.

Laboratory Tests

If there is a lack of therapeutic response, KOH smears, cultures, or other diagnostic methods should be repeated.

Carcinogenesis, Mutagenesis, Impairment of Fertility

No long-term animal studies have been performed to evaluate the carcinogenic potential of nystatin. No studies have been performed to determine the mutagenicity of nystatin or its effects on male or female fertility.

Pregnancy

Teratogenic Effects

Category C.

Animal reproduction studies have not been conducted with any nystatin cream. It also is not known whether this cream can cause fetal harm when used by a pregnant woman or can affect reproductive capacity. Nystatin cream should be prescribed for a pregnant woman only if the potential benefit to the mother outweighs the potential risk to the fetus.

Nursing Mothers

It is not known whether nystatin is excreted in human milk. Caution should be exercised when nystatin is prescribed for a nursing woman.

Pediatric Use

Safety and effectiveness have been established in the pediatric population from birth to 16 years.

(See DOSAGE AND ADMINISTRATION)

Geriatric Use

Clinical studies with nystatin cream did not include sufficient numbers of subjects aged 65 years and older to determine whether they respond differently than younger subjects. Other reported clinical experience has not identified differences in responses between elderly and younger patients, but greater sensitivity of some older individuals cannot be ruled out.

ADVERSE REACTIONS

The frequency of adverse events reported in patients using nystatin cream is less than 0.1%. The more common events that were reported include allergic reactions, burning, itching, rash, eczema, and pain on application.

(See PRECAUTIONS: General.)

DOSAGE AND ADMINISTRATION

Adults and Pediatric Patients (Neonates and Older)

Apply liberally to affected areas twice daily or as indicated until health is complete.

HOW SUPPLIED

Nystatin Cream, USP, 100,000 units per gram is a yellow to light green color cream available as follows:

NDC 68071-2887-3 30 g tube

STORAGE AND HANDLING

Store at 20°C to 25°C (68°F to 77°F); excursions permitted between 15°C and 30°C (59°F and 86°F) [see USP Controlled Room Temperature]. Avoid freezing.



Manufactured by:

TORRENT PHARMACEUTICALS LTD., Pithampur-454775, INDIA.

Manufactured for:

TORRENT PHARMA INC., Basking Ridge, NJ 07920

8088981 2022 August

PACKAGE LABEL.PRINCIPAL DISPLAY PANEL



NYSTATIN					
nystatin cream					
Product Information					
Product Type	HUMAN PRESCRIPTION DRUG	N Item Code NDC:680 (Source) 595)			-2887(NDC:13668-
Route of Administration	TOPICAL				
Active Ingredient/Active	Moiety				
Ingredie	ent Name		Basis of S	Strength	Strength
NYSTATIN (UNII: BDF101C72E) (NY	STATIN - UNII:BDF101C72E)		NYSTATIN		100000 U in 1 g
Inactive Ingredients					
	Ingredient Name				Strength
ALUMINUM HYDROXIDE (UNII: 5Q					
CETEARETH-15 (UNII: 867H4YOZ 8	3Z)				
CETEARETH-15 (UNII: 867H4YOZ 8 DIMETHICONE (UNII: 92RU3N3Y1C	3Z)				
CETEARETH-15 (UNII: 867H4YOZ 8 DIMETHICONE (UNII: 92RU3N3Y1C	3Z))) I: 2300U9XXE4)				
CETEARETH-15 (UNII: 867H4YOZ 8 DIMETHICONE (UNII: 92RU3N3Y1C GLYCERYL MONOSTEARATE (UNI METHYLPARABEN (UNII: A2I8C7HI	3Z))) I: 2300U9XXE4) 9T)				
CETEARETH-15 (UNII: 867H4YOZ 8 DIMETHICONE (UNII: 92RU3N3Y1C GLYCERYL MONOSTEARATE (UNI METHYLPARABEN (UNII: A2I8C7HI PETROLATUM (UNII: 4T6H12BN9U	3Z))) I: 2300U9XXE4) 9T))				
CETEARETH-15 (UNII: 867H4YOZ 8 DIMETHICONE (UNII: 92RU3N3Y1C GLYCERYL MONOSTEARATE (UNI METHYLPARABEN (UNII: A2I8C7HI PETROLATUM (UNII: 4T6H12BN9U POLYOXYL 8 STEARATE (UNII: 2P	3Z))) I: 2300U9XXE4) 9T)) 9L47VI5E)				
CETEARETH-15 (UNII: 867H4YOZ 8 DIMETHICONE (UNII: 92RU3N3Y1C GLYCERYL MONOSTEARATE (UNI METHYLPARABEN (UNII: A218C7HI PETROLATUM (UNII: 4T6H12BN9U POLYOXYL 8 STEARATE (UNII: 2P PROPYLENE GLYCOL (UNII: 6DC90	3Z))) I: 2300U9XXE4) 9T)) 9L47VI5E) Q167V3)				
CETEARETH-15 (UNII: 867H4YOZ & DIMETHICONE (UNII: 92RU3N3Y1C GLYCERYL MONOSTEARATE (UNI METHYLPARABEN (UNII: A2I8C7HI PETROLATUM (UNII: 4T6H12BN9U POLYOXYL 8 STEARATE (UNII: 2P PROPYLENE GLYCOL (UNII: 6DC90 PROPYLPARABEN (UNII: Z8IX2SC1 SORBITOL (UNII: 506T60A25R)	BZ))) I: 2300U9XXE4) 9T)) 9L47VI5E) Q167V3) LOH)				
CETEARETH-15 (UNII: 867H4YOZ & DIMETHICONE (UNII: 92RU3N3Y1C GLYCERYL MONOSTEARATE (UNI METHYLPARABEN (UNII: A218C7HI PETROLATUM (UNII: 4T6H12BN9U POLYOXYL 8 STEARATE (UNII: 2P PROPYLENE GLYCOL (UNII: 6DC90	BZ))) I: 2300U9XXE4) 9T)) 9L47VI5E) Q167V3) LOH)				
CETEARETH-15 (UNII: 867H4YOZ & DIMETHICONE (UNII: 92RU3N3Y1C GLYCERYL MONOSTEARATE (UNI METHYLPARABEN (UNII: A218C7HI PETROLATUM (UNII: 4T6H12BN9U POLYOXYL 8 STEARATE (UNII: 2P PROPYLENE GLYCOL (UNII: 6DC90 PROPYLENE GLYCOL (UNII: 6DC90 PROPYLPARABEN (UNII: 281X2SC1 SORBITOL (UNII: 506T60A25R) TITANIUM DIOXIDE (UNII: 15F1X9V	BZ))) I: 2300U9XXE4) 9T)) 9L47VI5E) Q167V3) LOH)				
CETEARETH-15 (UNII: 867H4YOZ & DIMETHICONE (UNII: 92RU3N3Y1C GLYCERYL MONOSTEARATE (UNII METHYLPARABEN (UNII: A2I8C7HI PETROLATUM (UNII: 4T6H12BN9U POLYOXYL 8 STEARATE (UNII: 2P PROPYLENE GLYCOL (UNII: 6DC90 PROPYLPARABEN (UNII: Z8IX2SC1 SORBITOL (UNII: 506T60A25R) TITANIUM DIOXIDE (UNII: 15FIX9V PRODUCT Characteristics	BZ))) I: 2300U9XXE4) 9T)) 9L47VI5E) Q167V3) LOH)		Score		

Fla	avor	Imprint Code						
Cc	ontains							
Pa	ackaging							
#	ltem Code	Package Description	Marketing Start Date	Marketing End Date				
1	NDC:68071- 2887-3	30 g in 1 TUBE; Type 0: Not a Combination Product	11/22/2022					
Marketing Information								
	Marketing Category	Application Number or Monograph Citation	Marketing Start Date	Marketing End Date				
	category							

Labeler - NuCare Pharmaceuticals,Inc. (010632300)

Establishment

Name	Address	ID/FEI	Business Operations
NuCare Pharmaceuticals, Inc.		010632300	relabel(68071-2887)

Revised: 11/2022

NuCare Pharmaceuticals, Inc.